Skip to main navigation Skip to search Skip to main content

Synthesis and evaluation of radioiodine-labelled CP-118,954 for the in-vivo imaging of acetylcholinesterase

  • Iljung Lee
  • , Yearn Seong Choe
  • , Eun Kyoung Ryu
  • , Byoung Wook Choi
  • , Joon Young Choi
  • , Yong Choi
  • , Kyung Han Lee
  • , Byung Tae Kim
  • Sungkyunkwan University
  • Hanbat National University

Research output: Contribution to journalArticlepeer-review

Abstract

Alzheimer's disease (AD) is characterized by reduced acetylcholinesterase (AChE) activity in the post-mortem tissues of AD patients. Therefore, AChE has been an attractive target for the diagnosis of AD. In the present study, 5,7-dihydro-3-[2-(1-(phenylmethyl)-4-piperidinyl)ethyl]-6H-pyrrolo[3,2-f]-1,2-benzisoxazol-6-one (CP-118,954), a potent AChE inhibitor, was labelled with radioiodine and evaluated as an AChE imaging agent for SPECT.

Original languageEnglish
Pages (from-to)561-566
Number of pages6
JournalNuclear Medicine Communications
Volume28
Issue number7
DOIs
StatePublished - Jul 2007
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • 954
  • Acetylcholinesterase
  • Alzheimer's disease

Fingerprint

Dive into the research topics of 'Synthesis and evaluation of radioiodine-labelled CP-118,954 for the in-vivo imaging of acetylcholinesterase'. Together they form a unique fingerprint.

Cite this